Rasonque’s speedy approval — just a month after a completed submission — represents a paradigm shift for a notoriously deadly cancer and begins what analysts see as a highly lucrative drug launch.
An article from
Dive Brief
Rasonque’s speedy approval — just a month after a completed submission — represents a paradigm shift for a notoriously deadly cancer and begins what analysts see as a highly lucrative drug launch.
Published Aug. 26, 2026
Courtesy of Revolution Medicines
FDA approves Revolution Medicines' Rasonque for metastatic pancreatic cancer. Phase 3 trials show a 60% reduced death risk vs…
In a late-stage trial, people who got Revolution Medicines’ Rasonque, or daraxonrasib, lived about twice as long as people who…
The US FDA on Wednesday approved Revolution Medicines' Rasonque for advanced pancreatic cancer, opening a new treatment option…
The FDA has approved a life-extending treatment for advanced pancreatic cancer — the first such therapy to attack a genetic cause…
The drug, Rasonque, nearly doubled median overall survival compared with standard chemotherapy in a 500-patient trial
The U.S. Food and Drug Administration on Wednesday approved Revolution Medicines’ targeted drug for adults with metastatic…
